Obesity in Hispanic Children with Leukemia

西班牙裔白血病儿童肥胖

• 批准号: 6916519
• 负责人: JACQUES G BAILLARGEON
• 金额: $ 7.3万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-01 至 2006-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6916519
• 关键词: Hispanic Americans; adolescence (12-20); asparaginase; biomarker; body composition; cancer risk; child (0-11); children; clinical research; comorbidity; dosage; gender difference; human subject; leukemia; longitudinal human study; neoplasm /cancer chemotherapy; neoplasm /cancer relapse /recurrence; obesity; patient oriented research; socioeconomics

DESCRIPTION (provided by applicant): Obesity has long been recognized as one of the most frequently occurring late effects after therapy for childhood acute lymphoblastic leukemia (ALL). A number of factors, including exposure to corticosteroids, exposure to cranial irradiation, and diminished exercise capacity reportedly contribute to increased rates of obesity among ALL survivors. The development of obesity during or following ALL treatment places survivors at increased risk for hypertension, type II diabetes, cardiovascular disease, persistent adulthood obesity, and recurrence of cancer. Childhood cancer patients who are already obese at the time of diagnosis represent a particular challenge for the oncologist. Obesity may complicate chemotherapy dose determination. Moreover, treatment-related weight gain may exacerbate the obese patient's already increased risk for many short- and long-term health effects. In view of the growing epidemic of childhood obesity in the general population, understanding the relationship between obesity status at the initiation of ALL therapy and weight gain and associated medical problems both during and following treatment is critically important. Because Hispanic adolescents exhibit exceedingly high rates of obesity, these research questions hold particular relevance to Hispanic Americans. The present study will rely on a historic cohort of 425 pediatric ALL patients treated at one of four institutions that comprise the South Texas Pediatric CCOP between 1990-2000. This patient population, which is 80% Hispanic, provides a unique opportunity to examine the impact of obesity at diagnosis on treatment, survivorship, and subsequent weight gain patterns. Our preliminary findings show that 18% of the patient population was obese and 22% is at risk for obesity at the time of diagnosis. The primary goals of the present study are to: 1) identify risk factors for obesity among ALL patients both during and following completion of chemotherapy; 2) quantify the extent of chemotherapy dose reduction in obese ALL patients; and 3) assess obesity as a prognostic factor in ALL patients.

描述（由申请人提供）： 长期以来，肥胖症已被认为是治疗儿童急性淋巴细胞白血病后最常见的后期作用之一（全部）。许多因素，包括暴露于皮质类固醇，暴露于颅骨照射以及运动能力下降，据报道有助于所有幸存者的肥胖率提高。在所有治疗期间或之后，肥胖的发展使幸存者处于高血压，II型糖尿病，心血管疾病，持续的成年肥胖症和癌症复发的风险增加。诊断时已经肥胖的儿童癌症患者对肿瘤学家来说是一个特殊的挑战。肥胖可能使化学疗法剂量确定复杂化。此外，与治疗相关的体重增加可能会加剧肥胖患者已经增加许多短期和长期健康影响的风险。鉴于一般人群中儿童肥胖的流行日益流行，在治疗期间和之后，了解所有疗法和体重增加和相关的医疗问题时肥胖状态之间的关系至关重要。由于西班牙裔青少年表现出极高的肥胖率，因此这些研究问题与西班牙裔美国人特别相关。本研究将依靠历史悠久的425个小儿队列，所有在1990 - 2000年之间的四个机构之一接受治疗的所有患者。该患者人群为80％的西班牙裔人，提供了一个独特的机会，可以检查肥胖对治疗，生存和随后的体重增加模式的影响。我们的初步发现表明，18％的患者人群肥胖，诊断时有22％的肥胖风险。本研究的主要目标是：1）确定化学疗法完成期间和之后所有患者肥胖的危险因素； 2）量化肥胖所有患者的化学疗法降低程度； 3）将肥胖视为所有患者的预后因素。